E
Sangamo Therapeutics, Inc. SGMO
$0.44 $0.013.48% NASDAQ
Recommendation
Prev Close
$0.44
Volume
427,525
Avg Vol (90D)
6,257,707
Market Cap
$148.12M
Dividend & Yield
--
52-Week Range
$0.38 - $2.84
P/E (TTM)
--
EPS (TTM)
-$0.45
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503
12/2/2025 - GuruFocus
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of ...
12/2/2025 - GuruFocus
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
12/2/2025 - Globe Newswire
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive
11/23/2025 - Simply Wall St
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission
11/21/2025 - GuruFocus
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in ...
11/21/2025 - GuruFocus
FDA Accepts Sangamo's Request For Rolling BLA Submission For Fabry Disease Gene Therapy Candidate
11/21/2025 - Nasdaq News: Markets
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
11/21/2025 - Globe Newswire
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages
11/21/2025 - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Strong Sell Rating by Wall Street Zen
11/16/2025 - MarketBeat
Research Analysts Offer Predictions for SGMO FY2025 Earnings
11/13/2025 - MarketBeat
Q4 Earnings Forecast for SGMO Issued By HC Wainwright
11/12/2025 - MarketBeat
Sangamo Therapeutics (SGMO) Is Down 21.1% After Nasdaq Compliance Extension and Q3 Revenue Decline - Has The Bull Case Changed?
11/9/2025 - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS
11/8/2025 - MarketBeat
Sangamo Therapeutics (SGMO) Faces Downgrade and PT Reduction by Barclays SGMO Stock News
11/7/2025 - GuruFocus
Sangamo Therapeutics (SGMO): Evaluating Valuation After Nasdaq Extension and Latest Earnings Decline
11/7/2025 - Simply Wall St
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
11/7/2025 - SeekingAlpha
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
11/7/2025 - Seeking Alpha: Transcripts
Sangamo Therapeutics Inc (SGMO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ...
11/6/2025 - GuruFocus
Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript
11/6/2025 - GuruFocus
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
11/6/2025 - Zacks Investment Research
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
11/6/2025 - GuruFocus
Sangamo Therapeutics (SGMO) Projects Funding into 2026 Despite Cash Decline
11/6/2025 - GuruFocus
Sangamo Therapeutics Inc Reports Q3 EPS of -$0.11, Missing Estimates; Revenue Falls to $0. ...
11/6/2025 - GuruFocus
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
11/6/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$32.88M
EBITDA (TTM)
-$103.48M
EBIT (TTM)
-$107.73M
Net Income (TTM)
-$108.91M
Balance Sheet
Total Assets (Q)
$88.64M
Total Debt (Q)
$25.42M
Total Liabilities (Q)
$82.40M
Book Value Per Share (Q)
$0.0194
Cash Flow
Cash from Operations (TTM)
-$76.16M
Cash from Investing (TTM)
$1.24M
Cash from Financing (TTM)
$62.94M
Net Change in Cash (TTM)
-$10.17M
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 16 and 20 (est)
Price History
Loading...
Beta
0.38
7-Day Total Return
3.97%
30-Day Total Return
-31.70%
60-Day Total Return
-15.30%
90-Day Total Return
-26.63%
Year to Date Total Return
-61.04%
1-Year Total Return
-79.53%
2-Year Total Return
-9.20%
3-Year Total Return
-87.56%
5-Year Total Return
-95.54%
52-week Low
Nov 20, 2025 - $0.38
52-week High
Dec 17, 2024 - $2.84
Valuation
Market Cap
$148.12M - Micro Cap
Enterprise Value
$143.93M
Price/Sales (TTM)
4.08
Price/Book (Q)
22.69
Dividends and Shares
Shares Outstanding
304.27
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sangamo.com
Phone Number
510 970 6000
Address
501 Canal Blvd
Richmond, CA 94804
Country
United States
Year Founded
1995
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed